CABA

Cabaletta Bio, Inc. is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Headquartered in Philadelphia, Pennsylvania, Cabaletta focuses on creating Chimeric Antigen Receptor T cell therapies and Chimeric Autoantibody Receptor T cell therapies specifically designed to reset the immune system in patients with autoimmune conditions. The company's lead program targets diseases such as myasthenia gravis, pemphigus vulgaris, and systemic lupus erythematosus. Cabaletta's approach involves engineering a patient's own T cells to selectively eliminate the B cells that produce disease-causing autoantibodies, potentially providing long-lasting remission without chronic immunosuppression. The company's technology platform builds on CAR-T cell therapy concepts originally developed for cancer treatment, adapting them for autoimmune applications. Cabaletta collaborates with the University of Pennsylvania and has assembled a team with expertise in immunology, cell therapy manufacturing, and autoimmune disease biology. The company is advancing multiple product candidates through preclinical and clinical development stages, seeking to address significant unmet needs in autoimmune disease treatment where current therapies often require lifelong medication with substantial side effects.